Background: The total cost of treating otitis media in the United States alone is estimated at > 3.5 billion dollars annually. Therefore treatment approaches that reduce the cost of managing otitis media can have a large impact on overall health care costs.
Methods: In this study cost effectiveness factors of various antimicrobial agents, such as adverse events and overall patient acceptance, were examined.
Results: Decreased patient acceptance and higher incidence of adverse events had a negative impact on the cost of treatment. Amoxicillin/clavulanate, cefprozil, erythromycin/sulfisoxazole and trimethoprim/sulfamethoxazole were found to be associated with decreased patient acceptance compared with cefixime. Cefixime also had the lowest number of adverse events of any of the drugs used. Amoxicillin had the lowest total cost for a single course of treatment, exclusive of costs of recurrence, which were examined in a previous study.
Conclusion: This study concluded that in cases in which several antibiotics may be clinically effective, comparative tolerability and patient acceptance data should be considered for selection of appropriate therapy. High compliance and lower morbidity can result in lower costs and better quality of life.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00006454-199702001-00008 | DOI Listing |
J Med Internet Res
January 2025
Indiana University, Indianapolis, IN, United States.
Background: Heart failure (HF) is one of the most common causes of hospital readmission in the United States. These hospitalizations are often driven by insufficient self-care. Commercial mobile health (mHealth) technologies, such as consumer-grade apps and wearable devices, offer opportunities for improving HF self-care, but their efficacy remains largely underexplored.
View Article and Find Full Text PDFEpidemiol Serv Saude
January 2025
Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brasil.
Objective: To assess adherence to and completeness of vaccination schedules against human papillomavirus (HPV) and hepatitis A and B among transgender women and travestis in São Paulo, capital city of São Paulo state.
Methods: This was a secondary data analysis of the multicenter TransOdara study. Data were collected from 403 transgender women and travestis aged 18 years or older, recruited through respondent-driven sampling between December 2019 and October 2020.
J Craniofac Surg
January 2025
Scar and Wound Treatment Center, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
Background: Compared with direct linear resection, the triangular flap insertion method is a correction method that purportedly reduces the incision tension of dog ears deformity. Randomized clinical trials comparing these 2 methods seem to be limited or absent.
Objective: A randomized study was planned to compare the cosmetic effect and scar in the defect area between the triangular flap insertion method and direct linear resection in the repair of dog ear deformities after the suture of the facial circular defect.
J Acquir Immune Defic Syndr
November 2024
Department of Health Policy & Management, University of North Carolina, Chapel Hill, NC, USA.
Background: Consistent evidence shows stigma impedes healthcare access in people living with HIV (PLWH) and men who have sex with men (MSM). We evaluated the impact of a stigma reduction training for providers whose design was informed by direct observation of their clinical behaviors obtained through visits by incognito standardized patient (SP).
Setting: We conducted this study in in sexually transmitted infection clinics in Guangzhou, China.
Inflamm Bowel Dis
January 2025
Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petach Tikva 4920235, Israel.
Background And Aims: Patients with very early-onset inflammatory bowel disease (VEO-IBD), with an age of onset < 6 years, can present with severe manifestations and may require biologic therapy. Infliximab and adalimumab are approved for induction and maintenance in pediatric IBD patients but are licensed only above the age of 6 years. Effectiveness and safety data on adalimumab in this patient population are lacking.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!